Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CAR T-cells targeting CD117 effectively eliminate mast cells in preclinical models of advanced systemic mastocytosis.

Leukemia·2026
Same author

Protocol: A multi-factorial, multi-centre study, for biomarker identification in healthy controls for comparison to babies with moderate-severe NESHIE.

PloS one·2026
Same author

An epigenetic perspective on neonatal encephalopathy with suspected hypoxic ischaemic encephalopathy.

Clinical epigenetics·2025
Same author

Predicting cerebral palsy and 18-month neurodevelopmental outcome in infants with presumed hypoxic ischaemic encephalopathy: role of general movements assessment and early neurological examination.

Frontiers in pediatrics·2025
Same author

Minimal impact of feed intolerance during therapeutic hypothermia for hypoxic ischaemic encephalopathy in a South African cohort with a standardised feeding regimen.

Frontiers in pediatrics·2025
Same author

Effect of adipose-derived mesenchymal stromal/stem cells on mouse mammary tumour growth and formation of lung metastases.

Current research in translational medicine·2025
Same journal

C26:0-lysophosphatidylcholine in X-linked adrenoleukodystrophy.

Pharmacology & therapeutics·2026
Same journal

The CircRNA/miRNA axis in breast cancer: From molecular mechanisms to clinical translation.

Pharmacology & therapeutics·2026
Same journal

Glymphatic-meningeal lymphatic dysfunction in epilepsy: novel mechanistic insights and therapeutic avenues.

Pharmacology & therapeutics·2026
Same journal

The neurovascular unit under siege: Molecular mechanisms and potential drug target for cerebral edema.

Pharmacology & therapeutics·2026
Same journal

A-type potassium channels in pain signaling: Fundamental mechanisms and pathophysiological roles.

Pharmacology & therapeutics·2026
Same journal

GPCR crosstalk beyond obligate dimerisation: Effector coincidence detection, compartmentation, and pharmacological implications.

Pharmacology & therapeutics·2026
See all related articles

Related Experiment Video

Updated: May 27, 2026

Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans
08:21

Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans

Published on: July 21, 2023

Cardiovascular pharmacogenetics.

Renier Myburgh1, Warren E Hochfeld, Tyren M Dodgen

  • 1Department of Immunology, Faculty of Health Sciences, University of Pretoria, South Africa.

Pharmacology & Therapeutics
|November 30, 2011
PubMed
Summary
This summary is machine-generated.

Human genetic variations influence drug response and adverse reactions in cardiovascular disease treatment. Understanding these genetic factors can optimize drug efficacy and minimize toxicity through personalized medicine approaches.

More Related Videos

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

Related Experiment Videos

Last Updated: May 27, 2026

Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans
08:21

Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans

Published on: July 21, 2023

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

Area of Science:

  • Pharmacogenetics
  • Cardiovascular Medicine
  • Genetics

Background:

  • Human genetic variations, including single nucleotide polymorphisms and structural variations, contribute to diverse clinical responses to pharmacotherapeutic drugs.
  • These variations impact the likelihood of adverse drug reactions and the achievement of therapeutic success.

Purpose of the Study:

  • To review key studies in cardiovascular pharmacogenetics.
  • To highlight genetic variations influencing drug treatment outcomes in cardiovascular disease.
  • To describe genetic associations with drug efficacy and toxicity.

Main Methods:

  • Review of key studies in cardiovascular pharmacogenetics.
  • Analysis of genetic associations with drug efficacy and toxicity.
  • Examination of genetic variability in pharmacokinetics and pharmacodynamics.

Main Results:

  • Genetic variations play a role in drug efficacy and toxicity in cardiovascular medicine.
  • Variability in drug metabolizing enzymes (pharmacokinetics) and drug targets (pharmacodynamics) are key factors.
  • Identified genetic associations provide functional insights into drug response.

Conclusions:

  • Genetic variations significantly affect cardiovascular drug treatment outcomes.
  • Understanding these genetic underpinnings can lead to the development of predictive genetic tests.
  • The goal is to minimize drug toxicity and optimize therapeutic efficacy in cardiovascular medicine.